reSee.it - Related Video Feed

Tim Ferriss interviews John Crowley, the chairman and CEO of Amicus Therapeutics, who has a remarkable story rooted in personal tragedy and triumph. Crowley’s journey began with the diagnosis of his two children with Pompe disease, a severe neuromuscular disorder. This prompted him to leave his job and become an entrepreneur, co-founding Nova Pharmaceuticals, which focused on developing treatments for the disease. After successfully raising funds and conducting research, Nova was acquired by Genzyme for nearly $200 million. Crowley’s family story gained national attention, leading to a book titled "The Cure" by Geeta Anand and a film adaptation called "Extraordinary Measures." He emphasizes the importance of resilience and determination in the face of adversity, sharing how his children’s diagnoses motivated him to fight for their lives and seek innovative treatments. He highlights the emotional toll of navigating the healthcare system and the urgency of finding effective therapies. In addition to his entrepreneurial endeavors, Crowley served as a commissioned officer in the U.S. Navy Reserve, where he was assigned to the Joint Special Operations Command. He discusses the parallels between military service and entrepreneurship, particularly the need for persistence and the ability to adapt under pressure. Crowley reflects on his upbringing in New Jersey, the loss of his father at a young age, and how these experiences shaped his character and drive. He stresses the importance of community support and the lessons learned from his family’s challenges. His children, now young adults, have benefited from the treatments developed through his efforts, although he acknowledges that the therapies are not cures. The conversation touches on the future of medicine, particularly advancements in gene therapy and the potential to extend human life. Crowley believes we are on the brink of a golden age in healthcare, where understanding human genetics could lead to breakthroughs in treating various diseases, including more common conditions like cancer and Alzheimer’s. Crowley advocates for a patient-centric approach in biotechnology, emphasizing the need to focus on individual lives and the impact of treatments. He shares insights on balancing work and family life, the importance of being present for loved ones, and the value of time. He concludes with a message about the significance of community and the lessons learned from his children, encouraging others to embrace diversity and resilience in their own lives.

In this episode of the All In podcast, the hosts discuss various topics, starting with Chamath's location in Europe and the unusual weather patterns he observed, which he attributes to climate change. The conversation shifts to Biogen's newly FDA-approved Alzheimer's drug, Aducanumab, the first new treatment in nearly two decades. Friedberg explains that while the drug does not cure Alzheimer's, it may slow its progression. The approval process was controversial, with three FDA advisory panel members resigning due to concerns over the drug's modest efficacy. The hosts debate the implications of the drug's high price of $56,000 per year, considering the ethical questions surrounding pharmaceutical pricing and the responsibility of insurance companies. Chamath highlights the demographic disparities in Alzheimer's prevalence, noting that the disease disproportionately affects women and minorities. He also discusses the historical context of failed Alzheimer's drugs and the potential for this approval to stimulate further research and innovation in the field. The discussion continues with a critique of the FDA's approval process, questioning the rationale behind approving a drug with limited evidence of clinical benefit. Sacks argues for a more lenient approach to drug approvals for terminal illnesses, suggesting that patients should have access to potentially helpful treatments. The hosts also touch on the economic implications of high drug prices and the challenges posed by Medicare's reimbursement policies. As the conversation evolves, they explore broader themes of innovation, competition, and the regulatory landscape in biotechnology, emphasizing the need for a balance between safety and accessibility. The episode concludes with reflections on the future of healthcare, the importance of fostering innovation, and the societal implications of current policies.

In this episode of TED Connects, hosts Whitney Pennington Rogers and Chris Anderson discuss the critical role of vaccines in public health with Dr. Seth Berkley, CEO of Gavi. Gavi was established to ensure that vaccines reach the developing world, successfully immunizing over 760 million children and preventing more than 13 million deaths. Berkley explains that vaccines stimulate the immune system to protect against diseases, but public skepticism arises from their success, leading to misconceptions about their safety. Berkley highlights the rapid development of Ebola vaccines and the need for a coordinated global response to the coronavirus pandemic. He emphasizes that while vaccines can be developed quickly, the timeline for widespread availability may take 12 to 18 months. The importance of diverse vaccine candidates and adaptive trial designs is discussed, as well as the need for global collaboration to ensure equitable access to vaccines. Berkley calls for viewing vaccines as a global public good, advocating for public sector financing and international cooperation to expedite development and distribution. He stresses the necessity of maintaining robust health systems and surveillance to prepare for future outbreaks. Ultimately, the conversation underscores the importance of science-driven decision-making and global solidarity in addressing public health crises.

In a conversation with Lex Fridman, Albert Bourla, CEO of Pfizer, discusses the complexities surrounding truth in public discourse, particularly regarding vaccines and public health. He emphasizes the historical significance of vaccines in saving lives and acknowledges the duality of perspectives on science and authority. Bourla reflects on the development of the COVID-19 vaccine, describing the intense pressure and investment of over $2 billion to expedite its creation during a global crisis. He asserts that the pharmaceutical industry must focus on breakthroughs that improve patient lives rather than solely on profit. Bourla addresses concerns about regulatory transparency, emphasizing that the FDA and other agencies operate under strict guidelines to ensure unbiased studies. He acknowledges the public's distrust of big pharma and stresses the importance of rebuilding trust through consistent integrity and communication. He discusses the necessity of vaccinating children, citing the risks of COVID-19, and highlights the development of Paxlovid, an antiviral treatment that significantly reduces hospitalization rates. Throughout the conversation, Bourla expresses hope for humanity's future, driven by ingenuity and the potential for scientific advancements to improve lives. He reflects on his personal motivations and the meaning of life, emphasizing the importance of creating a better world for future generations.